I'm LongbridgeAI, I can summarize articles.Glaukos gained 8.52% this week to close at $178.88, while the S&P 500 slipped 0.47%, leaving the stock roughly 8.99 percentage points ahead of the benchmark. The move was mostly one-way: after opening Monday at $164.71, the stock accelerated on Tuesday, pushed above $178 intraday on Wednesday, then held a 174-180 range into Friday’s close at $178.88. There was no major company-specific catalyst this week; the price ended well above its 20-day moving average.
The Week
Glaukos gained 8.52% this week to close at $178.88, while the S&P 500 slipped 0.47%, leaving the stock roughly 8.99 percentage points ahead of the benchmark. The move was mostly one-way: after opening Monday at $164.71, the stock accelerated on Tuesday, pushed above $178 intraday on Wednesday, then held a 174-180 range into Friday’s close at $178.88. There was no major company-specific catalyst this week; the price ended well above its 20-day moving average.
Analyst Ratings
Coverage totals 14 brokers: 10 rate it buy, 3 rate it overweight, and 1 is neutral. There are no underweight or sell ratings. The consensus recommendation is strong buy, with a consensus target of $199.31, about 11.42% above the latest close. Individual targets range from $172 to $225, so dispersion is not trivial. Within the 142-name medical device sector, Glaukos ranks 24th by broker rating.
The Week Ahead
Glaukos reports fiscal Q3 2026 results after Wednesday’s close on 28 October, with consensus estimates around -$0.18 EPS and $168m revenue — the key event to watch. On Tuesday, a batch of US macro prints including durable goods orders, new home sales and consumer confidence could also shape overall risk appetite.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.